MGC Derma launches new CBD-infused skincare product
MGC Pharmaceutical's (ASX:MXC) Derma division today launched a new skincare product in its Derma Plus collection — the CBD Herbal Replenish Cream, which is specifically developed for external skincare and relief from inflammatory skin conditions.
This latest piece of news follows on from the successful January launch of the CBD Herbal Repair Cream, which is formulated to treat dry, sensitive and flaky skin.
MGC Derma expects to launch a third Derma Plus product, the CBD Herbal Balm for oily and acne-prone skin, later this year.
Products in the Derma Plus range are dermatologically tested, research backed, and designed to improve the skin’s natural defence and to stimulate skin functions and regeneration. These products have been formulated with propriety CBD compounds extracted from the cannabis plant, produced by the MGC Botanic division. These products are available to MGC Derma’s base of global customers, and are for sale in regions where CBD-based products are permitted.
Encouragingly, an independent dermatological study in Europe last year found that these compounds deliver strong improvements across a range of skin conditions, including dry skin (71 per cent improvement), flaking skin (65 per cent improvement), and itching skin (86 per cent improvement).
With these kinds of positive testing results, 92 per cent of patients said they would continue using the cream.
Of course, as always, success is not guaranteed — consider your own personal circumstances before investing, and seek professional financial advice.
Co-founder, executive director and CEO, Roby Zomer, said that he was proud of the progress of MXC’s MGC Derma cosmetics subsidiary.
“MGC Derma Plus is a premium range designed to support the capacity for skin repair and prevent skin problems,” Zomer said. “The newest product will be a valuable addition to the range supporting our brand and increasing our presence within the CBD infused skincare space.”
This latest development comes hot on the heels of a recent string of good news from MXC. In April, the company unveiled its contract with the Maltese government to construct a state-of-the-art medical cannabis production and cultivation facility spanning 4,000 square metres. This makes MXC one of only five companies — and the only company in Australia — to be awarded a full medical cannabis production and cultivation contract.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.